Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: Study of 200 patients

Leukemia and Lymphoma

Volumn 46, Issue 10, 2005, Pages 1471-1476

  Batlle, Montserrat ^a   Ribera, Josep Maria ^a   Oriol, Albert ^a   Pastor, Cruz ^a   Mate, José Luis ^a   Fernández Avilés, Francesc ^a   Flores, Alonso ^a   Millá, Fuensanta ^a   Feliu, Evarist ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

2 microglobulin; CA 125; CA 15.3; LDH; Non Hodgkin's lymphoma; Prognosis

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; LACTATE DEHYDROGENASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PLEURA METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; VISCERAL METASTASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CA-15-3 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 26944456369     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500204781     Document Type: Article

References (31)

1. Kenemans P, Bast R, Yedima C, Price M, Hilgers J. CA 125 and polymorphic epithelial mucin as serum tumor markers. Cancer Rev 1988;11:119-144.
2. Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AAGM, Leguit P. CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 1994;47:263-265.
3. Brioschi PA, Bischof P, Rapin C, De Roten M, Irion O, Krauer F. Longitudinal study of CEA and CA 125 in ovarian cancer. Gynecol Oncol 1985;21:1-6.
4. Cruickshank DJ, Terry PB, Fullerton WT. CA 125-response assessment in epithelial ovarian cancer. Int J Cancer 1992;51:58-61.
5. Haga Y, Sakamoto K, Egami H, Yoshimura R, Mori K, Akagi M. Clinical significance of serum CA 125 values in patients witli cancers of the digestive system. Am J Med Sci 1986;292:30-34.
6. Simsek H, Kadayifci A, Okan E. Importance of serum CA 125 levels in malignant peritoneal mesothelioma. Tumour Biol 1996;17:1-4.
7. Kimura Y, Fujii T, Hamamoto K, Miyagawa N, Kataoka M, Iio A. Serum CA 125 level is a good prognostic indicator in lung cancer. Br J Cancer 1990;62:676-678.
8. Haga Y, Sakamoto K, Egami H, Yoshimura R, Akagi M. Elevation of serum CA 125 values in healthy individuals and pregnant women. Am J Med Sci 1986;292:25-29.
9. Imai A, Itoh T, Niwa K, Tamaya T. Elevated CA 125 serum levels in a patient with tuberculous peritonitis. Arch Gynecol Obstet 1991;248:157-159.
10. Bairey O, Blickstein D, Stark P, Prokocimer M, Nativ HM, Kirgner I et al. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1733-1738.
11. Dilek I, Ayakta H, Demir C, Metal C, Ozturk M. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol 2005;27:51-55.
12. Pabst Th, Ludwig Ch. CA 125: a tumor marker in Non-Hodgkin's lymphomas? J Clin Oncol 1995;13:1827-1828.
13. Ravoet Ch, Dargent JL, Le Moine W, Feremans W. CA 125 in primary mediastinal B-cell lymphoma with sclerosis. J Clin Oncol 1995;13:530.
14. Kubonishi I, Bandobashi K, Murata N, Daibata M, Ido E, Sonobe H. High serum levels of CA 125 and interleukin-6 in a patient with Ki-1 lymphoma. Br J Haematol 1997;98:450-452.
15. Lazzarino M, Orlandi E, Klersy C, Astori C, Brusamolino E, Corso A. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma. Correlation with tumor parameters and disease activity. Cancer 1998;82:576-582.
16. Ozguroglu M, Turna H, Demir, Doventas A, Demirelli F, Mandel NM. Usefulness of the epithelial tumor marker CA 125 in Non-Hodgkin's lymphoma. Am J Clin Pathol 1999;22:615-618.
17. Kutlik T, Varan A, Erbas B, Buyukpamukeu M. Serum CA 125 levels in children with Non-Hodgkin's Lymphoma. Pediatr Hematol Oncol 1999;16:311-319.
18. Vlasveld LT, Ermens AA, Sonnenberg AA, Pauwels P. Elevated serum concentrations due to expression by a diffuse large B-cell lymphoma. Anns Clin Biochem 2000;37:545-548.
19. Benboubker L, Valat C, Linassier C, Cartron G, Delain M, Bout M. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA 125 and LDH serum levels. Ann Oncol 2000;11:1485-1491.
20. Zidan J, Hussein O, Basher W, Zohar S. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hogkin's lymphoma. Oncologist 2004;9:417-421.
21. Morra E. The biological markers of non-hodgkin's lymphoma: their role in diagnosis, prognostic assessment and therapeutic strategy. Int J Biol Markers 1999;14:149-153.
22. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from multiple myeloma patient. J Immunol 1994;153:2102-2109.
23. World Health Organization. Classification of neoplastic diseases of hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November, 1997. J Clin Oncol 1999;17:3835-3849.
24. Cheson BD, Horning SJ, Coiffier B, Shipp AAA, Fisher RI, Connors JM. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:1244-1253.
25. Zacharos ID, Efstathiou SP, Petreli E, Geiorgiou G, Tsioulos DI, Mastorantonakis SE. The prognostic significance of CA 125 in patients with non-Hodgkin lymphoma. Eur J Haematol 2002;69:221-226.
26. Burney IA, Siddiqui T, Siddiqi I. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma. Correlation with tumor parameters and disease activity. Cancer 1999;85:755-756.
27. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
28. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood 2000;95:783-789.
29. Avilés A, Zepeda G, Díaz-Maqueo JC, Rodríguez L, Guzman R, García EL. Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma. Leuk Lymphoma 1992;7:135-138.
30. Coiffier B, Lepage E. Prognostic factors in large-cell lymphomas. Leuk Lymphoma 1993;10(Suppl):57-60.
31. Johnson PW, Whelan J, Longhurst S, Stepniewska K, Matthews J, Ames J. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer 1993;67:792-797.